NS-2359
Lua error in Module:Infobox at line 314: malformed pattern (missing ']').
NS-2359 (GSK-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant,[1] but was discontinued in 2009 when phase II clinical trials turned up disappointing results and did not support further effort by the company.[1] NS-2359 was also in clinical trials for the treatment of ADHD,[2] phase II having been completed in 2007.[3] A trial exploring the effect of NS-2359 on cocaine-experienced individuals is currently ongoing.[4]
Another scientific article on NS-2359 was recently (2011) published.[5] As can be seen from reading the abstract to the citation, the compound failed to perform in clinical trials for the treatment of depression.
See also
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." /><templatestyles src="Asbox/styles.css"></templatestyles>
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- ↑ 1.0 1.1 Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ http://clinicaltrials.gov/ct2/show/NCT00467428
- ↑ http://clinicaltrials.gov/ct2/show/NCT00032916
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- Pages with reference errors
- Infobox drug articles without a structure image
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Ethers
- Serotonin-norepinephrine-dopamine reuptake inhibitors
- Chloroarenes
- Tropanes
- Nervous system drug stubs
